Early Access Strategy: Incorporating Market Access Insights into Early Assets
The head of commercial for a top 20 pharma company was concerned that the adoption for their newly-approved drug were not meeting pre-launch expectations. The new brand team was tasked with identifying and removing hurdles to reimbursement. The NPP head was charged with determining the reason for the discrepancy between pre-launch guidance and post-launch experience. Artisan was brought into help identify the issues and recommend changes.
© 2021 SOURCE EXPLORER® All rights reserved